Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Immunotherapy with UCB or Haplo-identical Cells in High Risk Leukemia
NCT02508324Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2015
- Primary completion
- Jun 2022
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of umbilical cord blood in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Weill Cornell Medicine. Started Sep 2015; status: terminated.
02
Drugs
umbilical cord blood
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02508324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508324.